Salsalate: a pleotropic anti-inflammatory drug in the treatment of diabetes, obesity, and metabolic diseases
- PMID: 37758933
- DOI: 10.1007/s10787-023-01242-9
Salsalate: a pleotropic anti-inflammatory drug in the treatment of diabetes, obesity, and metabolic diseases
Abstract
Type two Diabetes Mellitus (T2DM) is a rising epidemic. Available therapeutic strategies have provided glycaemic control via HbA1c reduction but fail to provide clinically meaningful reduction in microvascular and macrovascular (cardiac, renal, ophthalmological, and neurological) complications. Inflammation is strongly linked to the pathogenesis of T2DM. Underlying inflammatory mechanisms include oxidative stress, endoplasmic reticulum stress amyloid deposition in the pancreas, lipotoxicity, and glucotoxicity. Molecular signalling mechanisms in chronic inflammation linked to obesity and diabetes include JANK, NF-kB, and AMPK pathways. These activated pathways lead to a production of various inflammatory cytokines, such as Interleukin (IL-6), tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP), which create a chronic low-grade inflammation and ultimately dysregulation of glucose homeostasis in the liver, skeletal muscle, and smooth muscle. Anti-inflammatory agents are being tested as anti-diabetic agents such as the IL-1b antagonist, Anakinra, the IL-1b inhibitor, Canakinuma, the IL-6 antagonists such as Tocilizumab, Rapamycin (Everolimus), and the IKK-beta kinase inhibitor, Salsalate. Salsalate is a century old safe anti-inflammatory drug used in the treatment of arthritis. Long-term safety and efficacy of Salsalate in the treatment of T2DM have been evaluated, which showed improved fasting plasma glucose and reduced HbA1C levels as well as reduced pro-inflammatory markers in T2DM patients. Current publication summarizes the literature review of pathophysiology of role of inflammation in T2DM and clinical efficacy and safety of Salsalate in the treatment of T2DM.
Keywords: AMP-activated protein kinase mitogen-activated protein kinase; Non-steroidal anti-inflammatory; Nuclear factor kappa B; Salsalate; Type 2 diabetes mellitus (T2DM).
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Expert Opin Investig Drugs. 2015 Mar;24(3):283-307. doi: 10.1517/13543784.2015.974804. Epub 2014 Oct 25. Expert Opin Investig Drugs. 2015. PMID: 25345753 Review.
-
Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).J Assoc Physicians India. 2019 Dec;67(12):65-74. J Assoc Physicians India. 2019. PMID: 31801334
-
Elevated Serum TNF-α Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance.J Obes. 2020 Jan 30;2020:5076858. doi: 10.1155/2020/5076858. eCollection 2020. J Obes. 2020. PMID: 32089876 Free PMC article.
-
Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus.Front Immunol. 2023 Mar 1;14:1125116. doi: 10.3389/fimmu.2023.1125116. eCollection 2023. Front Immunol. 2023. PMID: 36936906 Free PMC article.
-
Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.Inflammopharmacology. 2023 Aug;31(4):1683-1693. doi: 10.1007/s10787-023-01239-4. Epub 2023 May 19. Inflammopharmacology. 2023. PMID: 37208555 Free PMC article. Review.
Cited by
-
Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy?Front Endocrinol (Lausanne). 2024 May 15;15:1357859. doi: 10.3389/fendo.2024.1357859. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38812811 Free PMC article. Review.
References
-
- Egan DF, Shackelford DB, Mihaylova MM et al (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011(331):456–461 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous